Baumer Valuation
Is BALM3 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of BALM3 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: BALM3 (R$13) is trading below our estimate of fair value (R$46.68)
Significantly Below Fair Value: BALM3 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BALM3?
Key metric: As BALM3 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is BALM3's PE Ratio? | |
|---|---|
| PE Ratio | 7.4x |
| Earnings | R$13.49m |
| Market Cap | R$113.78m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.4x |
| Enterprise Value/EBITDA | 2.8x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does BALM3's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 16.6x | ||
7782 Sincere | 14.5x | n/a | JP¥3.2b |
IORB S.C. IOR | 31.7x | n/a | RON 111.6m |
4183 EPS Bio Technology | 16.8x | n/a | NT$572.4m |
VVEO3 CM Hospitalar S/A | 3.4x | 23.6% | R$614.7m |
BALM3 Baumer | 7.4x | n/a | R$113.8m |
Price-To-Earnings vs Peers: BALM3 is good value based on its Price-To-Earnings Ratio (7.4x) compared to the peer average (16.1x).
Price to Earnings Ratio vs Industry
How does BALM3's PE Ratio compare vs other companies in the Global Medical Equipment Industry?
| 10 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 10 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: BALM3 is good value based on its Price-To-Earnings Ratio (7.4x) compared to the Global Medical Equipment industry average (28x).
Price to Earnings Ratio vs Fair Ratio
What is BALM3's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 7.4x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate BALM3's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Centene
US$29.0b
Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.
C1NC34
US$341.36
7D
-2.2%
1Y
-4.1%
Universal Health Services
US$13.3b
Through its subsidiaries, owns and operates acute care hospitals, and outpatient and behavioral health care facilities.
U1HS34
US$292.61
7D
1.8%
1Y
n/a
Koninklijke Philips
€22.9b
Operates as a health technology company in North America, the Greater China, and internationally.
PHGN34
€153.92
7D
0%
1Y
52.7%